OPGx-BEST1 Shows Early Signals in Five Treated Participants
Opus Genetics reported low-dose Cohort 1 results from the open-label Phase I/II BIRD-1 study of subretinal OPGx-BEST1 in five adults with BEST1-related retinal disease. All five improved on at least one visual-function measure, four…
